A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015)

O&#39; Neil B H<sup>*</sup>; Scott A J; Ma W W; Cohen S J; Leichman L; Aisner D L; Menter A R; Tejani M A; Cho J K; Granfortuna J; Coveler L; Olowokure O O; Baranda J C; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen D J; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee A J; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes C L; Messersmith W A

doi:10.1093/annonc/mdv477

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015)

作者：O'Neil B H^*; Scott A J; Ma W W; Cohen S J; Leichman L; Aisner D L; Menter A R; Tejani M A; Cho J K; Granfortuna J; Coveler L; Olowokure O O; Baranda J C; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen D J; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee A J; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes C L; Messersmith W A

来源：Annals of Oncology, 2015, 26(12): 2505-2505.

DOI：10.1093/annonc/mdv477